Quantum-Si Incorporated Class A (QSI)

Over the past six months, Quantum-Si's stock price has experienced significant fluctuations and a general downward trend. As of February 3, 2026, the share price was $1.09, representing an 11.38% decrease from the prior week, and a 42.65% decrease over the past year. Key events impacting the stock include a Q2 2025 revenue fall, a Q1 2025 loss, speculation about a potential capital raise, weak fundamentals driven by market sentiment, and analyst ratings with a consensus "Hold" recommendation.

As of October 2025, the demand environment for Quantum-Si's products has strengthened in recent months. The company has suggested that sequential growth is likely to be modest in Q3 before accelerating in Q4, indicating a potential seasonality with stronger demand in the latter part of the year. The company's overall revenue needs a significant jump, which is anticipated with the introduction of its Proteus system.

Quantum-Si, Inc. is a life sciences company specializing in a universal single-molecule detection platform for Next-Generation Protein Sequencing (NGPS), aiming to digitize proteomic research for drug discovery and diagnostics. The company operates in the Healthcare sector, specifically in the Medical Devices and Life Sciences Tools and Services industries, and is also categorized under Discovery Tools and Electronics - Semiconductors. Its major products include Platinum® and Platinum® Pro NGPS instruments, the Carbon automated sample preparation instrument, library preparation kits, barcoding kits, sequencing kits, and Platinum Analysis Software. Quantum-Si's products are utilized in various applications such as antibody characterization, biomarker identification, protein identification, protein variants, protein barcoding, and post-translational modification analysis.

Quantum-Si, Inc. was founded in 2013 and is headquartered in Branford, Connecticut, United States. While the company's customer base has historically skewed towards academic researchers, most of its devices are now located internationally. A detailed breakdown of its specific international presence is not publicly available.

In the past year, Quantum-Si has received recognition but also faced scrutiny regarding its commercial viability and financial performance. The company was named "2023 Proteomics Company of the Year" and recognized for "Innovation by Design 2023." However, the company has faced challenges due to weak commercial traction, operating losses, competition, reliance on partners, and concerns about the unproven nature of its technology. Some analyses suggest that the stock price has been driven by "quantum hype" rather than strong financial performance.

Quantum-Si, Inc. has 205 institutional owners and shareholders holding a total of 82,723,976 shares. Institutional ownership accounts for 27.92% of the company, while individuals hold 21.54%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and ARK Investment Management LLC, among others.